UnknownPhase 4

Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion

United States360 participantsStarted 2020-08-05

Plain-language summary

Comparison among three different antithrombotic strategies after percutaneous LAA occlusion with a Watchman FLX LAAC device.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women ≥18 years of age * Successful LAAC procedure (device implanted without procedural or bleeding complication). * Patients contraindicated or unsuitable for long-term OAC. * History of AF (permanent or persistent or paroxysmal). * Written informed consent by the patient or designee if the patient is unable to consent Exclusion Criteria: * Life expectancy \< 2 years. * Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

What they're measuring

Composite of Stroke, Systemic Embolism, and Device-related Thrombosis

Timeframe: 1 year

Incidence of Major Bleeding Events

Timeframe: 1 year

Trial details

NCT IDNCT04502017

SponsorTexas Cardiac Arrhythmia Research Foundation

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-31

Contact for this trial

Domenico G Della Rocca, MD

7375296806 domenicodellarocca@hotmail.it

View on ClinicalTrials.gov More Device-Related Thrombosis trials